




Tirzepatide

Revised: November 15, 2023.

CASRN: 2023788-19-2



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of tirzepatide during breastfeeding. Because tirzepatide is a large peptide molecule with a molecular weight of 4814 Da, the amount in milk is likely to be low and absorption is unlikely because it is probably partially destroyed in the infant's gastrointestinal tract. Until more data become available, tirzepatide should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Glipizide, Glyburide, Insulin, Metformin, Miglitol

Substance Identification

Substance Name

Tirzepatide

CAS Registry Number

2023788-19-2

Drug Class

Breast Feeding

Lactation

Milk, Human

Hypoglycemic Agents

Incretins

Glucagon-Like Peptide-1 Agonists

GLP-1 Agonists